Ocular Therapeutix Inc
OCUL
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.23B
Close$
$-1.83
118.9% downside
Current Fair Value
118.9% downsideOvervalued by 118.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.23 Billion |
|---|---|
| Enterprise Value | $1.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.42 |
| Beta | 0.88 |
| Outstanding Shares | 224,099,410 |
Return
| Return on Equity | -49.95% |
|---|---|
| Return on Assets | -39.66% |
| Return on Invested Capital | -43.16% |
Valuation & Multiples
| P/E Ratio | -6.99 |
|---|---|
| PEG | -18.22 |
| Price to Sales | - |
| Price to Book Ratio | 4.85 |
| Enterprise Value to Revenue | 31.63 |
| Enterprise Value to EBIT | -5.57 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$12.56 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
$13.20 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 103.98% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.24%▼ 110.17% |
|---|---|
| Total Invested | $5.39M▼ 99.69% |
| Investors Holding | 9▼ 276.00% |
ESG Score
No data
About Ocular Therapeutix Inc
CEO: Antony Mattessich